George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,312.00
Bid: 1,314.50
Ask: 1,316.50
Change: -6.00 (-0.46%)
Spread: 2.00 (0.152%)
Open: 1,320.50
High: 1,323.00
Low: 1,304.00
Prev. Close: 1,318.00
PSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Financial Officer

13 Jan 2022 07:04

RNS Number : 2776Y
Persimmon PLC
12 January 2022
 

13 January 2022

Persimmon Plc

("Persimmon" or "the Group")

 

Appointment of Chief Financial Officer

 

The Board of Persimmon Plc is pleased to announce the appointment of Jason Windsor as Chief Financial Officer. Jason is expected to join in the summer and will become an Executive Director on the Board at that time. He will succeed Mike Killoran, who announced in July 2021 that he would be retiring in mid-January 2022 after more than 25 years with the Group.

 

Jason is an experienced finance executive who has established a strong track record in a variety of senior financial roles over the last 26 years. He has been Group Chief Financial Officer of Aviva PLC since 2019, having previously been Chief Financial Officer of both its UK Insurance and UK Life businesses, after originally joining the business in 2010. Prior to that he spent 15 years at Morgan Stanley, latterly as a Managing Director within its Investment Banking Division.

 

Roger Devlin, Persimmon's Chairman, said: "Jason is a well-respected and proven FTSE 100 CFO and we are delighted to have recruited someone of his calibre and experience as Chief Financial Officer to complement our strong management team. In his current role Jason has demonstrated an ability to deliver sustained financial and strategic progress while working in a large consumer-facing business. These skills will be highly relevant and transferable to Persimmon as we continue our drive to become the leading builder of good value, quality family homes in the UK. We look forward to welcoming him to the Group in the summer.

 

"I would also like to thank Mike Killoran once again for his significant contribution to the success of Persimmon over many years. Everyone at Persimmon wishes Mike well in his retirement."

 

Jason Windsor said: "I'm delighted to be joining the Group and excited by the opportunities ahead. Persimmon has a leading position in a critical sector of the UK economy and I'm looking forward to working with the team as they continue their journey to becoming Britain's best housebuilder, whilst maintaining industry-leading financial returns."

 

Mike Killoran will leave the Group as planned on 14 January 2022. With Jason expected to join in the summer, Dean Finch, Group Chief Executive, will assume interim responsibility for the finance function. Dean will be supported by Mike Smith, Group Financial Controller - Reporting, and Jim Wilkinson, Group Financial Controller - Operations.

 

Remuneration

 

Jason Windsor

 

All remuneration arrangements for Jason are consistent with the terms of the Directors' Remuneration Policy approved by shareholders at the AGM in April 2020. As Chief Financial Officer, Jason will receive an annual base salary of £675,000, which is the same as his salary at Aviva, and a pension allowance of 9% of salary in line with the contribution available for Persimmon's salaried employees. For 2022 Jason will also be able to participate in the Company's existing annual bonus plan up to a maximum of 175% of salary (with 50% of any bonus earned being deferred into Persimmon shares for three years), and the Performance Share Plan up to 200% of salary (based on performance over three years and subject to a further two year holding period). Jason's remuneration is at a similar level to his existing package at Aviva. As set out in the remuneration policy for the Executive Directors, a proportion of Jason's remuneration will be based on non-financial metrics including customer care and quality.

 

Jason will also receive awards to compensate for remuneration he is forfeiting on leaving his previous employer. These will remain subject to performance conditions where appropriate and reflect the value of the forfeited awards. The vesting timeline of the replacement awards will be the same as those which apply to the forfeited awards. Details will be disclosed in Persimmon's Directors' Remuneration Report for the year ending 31 December 2021.

 

Mike Killoran

 

Mike Killoran will receive his salary and benefits up until the date of his retirement on 14 January 2022. The Remuneration Committee has determined that Mike will be treated as a Good Leaver and he will therefore receive any bonus earned for the year ended 31 December 2021 and outstanding Performance Share Plan awards on a time pro-rated basis and subject to the performance conditions, in recognition of his significant contribution to the success of the Group over many years. Vesting will occur on the normal dates. Details of the remuneration arrangements relating to Mike Killoran can be found on the Group website at: www.persimmonhomes.com/corporate/investors/corporate-governance/board-of-directors.

 

Jason Windsor is also a director of General Accident PLC, a subsidiary of Aviva PLC. There are no further disclosures required in respect of Listing Rule 9.6.13.

 

For further information, please contact:

 

Citigate Dewe Rogerson

 

Kevin Smith / Jos Bieneman

 

Tel: +44 (0)20 7638 9571

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASFIFAEEESELF
Date   Source Headline
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company
8th Nov 20237:00 amRNSAppointment of Chief Financial Officer
7th Nov 20237:00 amRNSQ3 Trading Statement
3rd Nov 20231:15 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
10th Aug 20237:04 amRNSHalf Year Results
27th Jul 202310:13 amRNSDirectorate Change
10th Jul 20239:27 amRNSDirector Declaration
3rd Jul 20232:46 pmRNSTotal Voting Rights
1st Jun 20234:38 pmRNSTR-1: Notification of major holdings
1st Jun 20231:07 pmRNSBlock listing Interim Review
1st Jun 202311:06 amRNSTotal Voting Rights
3rd May 20235:00 pmRNSHolding(s) in Company
3rd May 20234:12 pmRNSDirector/PDMR Shareholding
2nd May 202311:13 amRNSTotal Voting Rights
26th Apr 20234:32 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 20234:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20233:05 pmRNSTotal Voting Rights
27th Mar 20233:44 pmRNSDirector/PDMR Shareholding
22nd Mar 20233:00 pmRNSAnnual Report 2022 and Notice of AGM 2023
13th Mar 20231:57 pmRNSDirectorate Change
13th Mar 202312:19 pmRNSUK Government Self Remediation Contract Signed
7th Mar 20235:33 pmRNSHolding(s) in Company
7th Mar 20237:04 amRNSDirector Declaration
6th Mar 20235:02 pmRNSHolding(s) in Company
1st Mar 20237:00 amRNSFull Year Results
12th Jan 20237:00 amRNSTrading Statement
1st Dec 20225:30 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20225:25 pmRNSVoting Rights and Capital
8th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:00 pmRNSTotal Voting Rights
1st Nov 20229:24 amRNSHolding(s) in Company
10th Oct 20222:24 pmRNSDirector/PDMR Shareholding
5th Oct 202210:26 amRNSHolding(s) in Company
4th Oct 20223:07 pmRNSDirector/PDMR Shareholding
3rd Oct 20222:12 pmRNSTotal Voting Rights
22nd Sep 20223:54 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.